Delayed
Nasdaq
01:12:49 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
9.425
USD
|
+4.96%
|
|
+1.89%
|
+0.27%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
225.6
|
17.31
|
19.16
|
28.72
|
-
|
Enterprise Value (EV)
1 |
123.7
|
-58.53
|
-16.88
|
9.425
|
-56.28
|
P/E ratio
|
-2.91
x
|
-0.56
x
|
-0.44
x
|
-1.23
x
|
-1.64
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
1.38
x
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-4.68
x
|
-
|
-
|
-
|
EV / EBITDA
|
-2,364,557
x
|
1,380,995
x
|
-
|
-
|
-
|
EV / FCF
|
-
|
1,304,394
x
|
-
|
-
|
-
|
FCF Yield
|
-
|
0%
|
-
|
-
|
-
|
Price to Book
|
-
|
0.27
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
2,335
|
1,983
|
2,038
|
3,199
|
-
|
Reference price
2 |
96.60
|
8.728
|
9.400
|
8.980
|
8.980
|
Announcement Date
|
3/24/22
|
3/22/23
|
4/10/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
-
|
12.5
|
-
|
-
|
-
|
EBITDA
|
-
|
-52.32
|
-42.38
|
-
|
-
|
-
|
EBIT
1 |
-
|
-54.39
|
-44.34
|
-45.78
|
-27.15
|
-43.05
|
Operating Margin
|
-
|
-
|
-354.71%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-54.65
|
-36
|
-43.04
|
-18
|
-48
|
Net income
1 |
-32.72
|
-54.65
|
-36
|
-43.04
|
-27.15
|
-43.05
|
Net margin
|
-
|
-
|
-288.03%
|
-
|
-
|
-
|
EPS
2 |
-66.30
|
-33.15
|
-15.60
|
-21.33
|
-7.275
|
-5.490
|
Free Cash Flow
|
-
|
-
|
-44.87
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-358.98%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/14/21
|
3/24/22
|
3/22/23
|
4/10/24
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
12.5
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-13.18
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-13.7
|
-15
|
-14.49
|
-14.07
|
-13.6
|
-2.169
|
-14.59
|
-10.28
|
-11.19
|
-9.724
|
-9.05
|
-9.05
|
-9.05
|
-9.05
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-17.35%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-14.02
|
-14.95
|
-7.947
|
-13.92
|
-13.36
|
-0.775
|
-14.3
|
-9.387
|
-10.44
|
-8.913
|
-9
|
-9
|
-9
|
-9
|
-
|
Net income
1 |
-14.02
|
-14.95
|
-7.947
|
-13.92
|
-13.36
|
-0.775
|
-14.3
|
-9.387
|
-10.44
|
-8.913
|
-9.05
|
-9.05
|
-9.05
|
-9.05
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-6.2%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-7.650
|
-5.250
|
-3.450
|
-6.000
|
-5.700
|
-0.4500
|
-7.200
|
-4.650
|
-5.100
|
-4.380
|
-2.950
|
-2.190
|
-2.150
|
-1.810
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/15/21
|
3/24/22
|
5/11/22
|
8/11/22
|
11/14/22
|
3/22/23
|
5/10/23
|
8/9/23
|
11/8/23
|
4/10/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
102
|
75.8
|
36
|
19.3
|
85
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-44.9
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-69.6%
|
-38.8%
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-31.8%
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
113.3
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
32.80
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-29.70
|
-19.10
|
-
|
-
|
-
|
Capex
1 |
-
|
1.27
|
0.73
|
0.4
|
1.9
|
1.9
|
Capex / Sales
|
-
|
-
|
5.82%
|
-
|
-
|
-
|
Announcement Date
|
5/14/21
|
3/24/22
|
3/22/23
|
4/10/24
|
-
|
-
|
Last Close Price
8.98
USD Average target price
33
USD Spread / Average Target +267.49% Consensus |
1st Jan change
|
Capi.
|
---|
| +0.27% | 28.72M | | +2.64% | 42.75B | | +47.70% | 41.61B | | +12.13% | 41.34B | | -8.83% | 26.59B | | +7.59% | 25.49B | | -22.58% | 18.12B | | +30.71% | 12.24B | | -1.77% | 11.76B | | +9.40% | 11B |
Other Biotechnology & Medical Research
|